Is doxepin a controlled substance?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 23, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Is Doxepin a Controlled Substance?

No, doxepin is not a federally controlled substance in the United States. This distinguishes it from most other pharmacologic treatments for insomnia, which are typically scheduled medications.

Regulatory Classification

  • Doxepin is explicitly noted as an exception among insomnia medications because it is not a controlled substance 1, 2
  • In contrast, other commonly used sleep medications carry controlled substance designations:
    • Benzodiazepines (temazepam, triazolam, estazolam) are Schedule IV controlled substances 3
    • Non-benzodiazepine hypnotics (zolpidem, eszopiclone, zaleplon) are Schedule IV controlled substances 3
    • Modafinil and armodafinil are Schedule IV controlled substances 3
    • Stimulants like methylphenidate and dextroamphetamine are Schedule II controlled substances 3
    • Carisoprodol is classified as a controlled substance due to abuse potential 3

Clinical Implications of Non-Controlled Status

  • The lack of controlled substance classification makes doxepin particularly advantageous for patients requiring long-term insomnia treatment without the regulatory burden and abuse concerns associated with scheduled medications 1, 2
  • Low-dose doxepin (3 mg and 6 mg) received FDA approval specifically for insomnia treatment, separate from its higher-dose antidepressant formulations 2, 4
  • At low doses used for insomnia, doxepin works primarily through selective histamine H₁ receptor antagonism rather than through mechanisms associated with abuse potential 4

Safety Profile Supporting Non-Controlled Status

  • Studies of up to 3 months duration showed no signal for tolerance, psychomotor impairment, rebound insomnia, or discontinuation symptoms with low-dose doxepin 4
  • Long-term use (5-15 years) at antidepressant doses has demonstrated safety and lack of adverse drug interactions, though this data pertains to higher doses than those used for insomnia 5
  • The most common adverse effects are sedation/sleepiness and headache, occurring at rates similar to or less than placebo 4

Important Caveats

  • While not a controlled substance, doxepin at higher doses (25-300 mg) used for depression is a tricyclic antidepressant with significant cardiotoxicity in overdose 6
  • The non-controlled status applies to all doses, but the safety profile and clinical use differ substantially between low-dose (1-6 mg) hypnotic formulations and higher-dose antidepressant formulations 2, 6

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.